Corticobasal Atrophy (Cba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal Atrophy (CBA), also known as Corticobasal Syndrome (CBS) with underlying corticobasal degeneration pathology, is a rare progressive neurodegenerative disorder characterized by asymmetric parkinsonism, cortical sensory deficits, and apraxia. It is classified as a tauopathy, sharing pathological features with progressive supranuclear palsy and frontotemporal dementia.[1]
Corticobasal Atrophy typically presents in the sixth to seventh decade of life, with progressive decline over 5-10 years. The disease affects both cortical and subcortical brain regions, leading to a constellation of motor and cognitive symptoms that often begin asymmetrically and spread to involve both sides of the body.[2]
Corticobasal Atrophy is characterized by abnormal accumulation of hyperphosphorylated tau protein in the brain. Unlike sporadic corticobasal degeneration, some cases of CBA have been associated with:[3]
MAPT gene mutations: Certain pathogenic variants in the MAPT (Microtubule-Associated Protein Tau) gene have been linked to familial cases of corticobasal syndrome.
Tau protein isoforms: The characteristic tau pathology in CBA involves all six isoforms of tau protein (3R and 4R), distinguishing it from some other tauopathies.
Tau astrogliopathy: Significant astrocytic pathology is a hallmark of CBA, with tau-positive astrocytes forming characteristic structures.
Corticobasal Atrophy presents with a combination of motor and cognitive symptoms, typically with marked asymmetry:[2]
Motor Symptoms:
Cortical Sensory Deficits:
Cognitive and Behavioral Symptoms:
Neuronal Loss and Atrophy:
Tau-positive Inclusions:
Ballooned Neurons:
Substantia Nigra Degeneration:
Corticobasal Atrophy is diagnosed based on clinical presentation:[4]
Core clinical features (required):
Supportive features:
MRI:
PET/SPECT:
CBA must be distinguished from:
No disease-modifying therapies exist for corticobasal atrophy. Treatment is symptomatic:[5]
Motor symptoms:
Cognitive/behavioral symptoms:
Several clinical trials are investigating potential treatments for corticobasal degeneration, including tau-targeted therapies and neuroprotective agents.
The study of Corticobasal Atrophy (Cba) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dickson DW, et al. Neuropathology of variants of progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2000;180(1-2):10-20. https://doi.org/10.1016/s0022-510x(00)00433-7
Lee SE, et al. Clinicopathological correlations in corticobasal degeneration. Neurology. 2011;77(2):156-162. https://doi.org/10.1212/WNL.0b013e318224afa8
Kouri N, et al. Corticobasal degeneration: A pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263-272. https://doi.org/10.1038/nrneurol.2011.43
Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. https://doi.org/10.1212/WNL.0b013e31827f0fee
Litvan I, et al. Current concepts: Differential diagnosis of dementia and movement disorders. Mov Disord. 2013;28(1):1-17. https://doi.org/10.1002/mds.25032
Murray R, et al. Neuropathological and clinical phenotype of corticobasal degeneration: An analysis of 100 cases. Brain. 2010;133(Pt 10):2945-2956. https://doi.org/10.1093/brain/awq200
Horimoto Y, et al. Long-term survival in corticobasal degeneration. Parkinsonism Relat Disord. 2000;6(4):231-234. https://doi.org/10.1016/s1353-8020(00)00036-5
Wenning GK, et al. The natural history of multiple system atrophy: A prospective European cohort study. Lancet Neurol. 2013;12(3):264-274. https://doi.org/10.1016/S1474-4422(12)70328-9
Komori T, et al. Correlation between neuropathologic findings and clinical features in corticobasal degeneration. Acta Neuropathol. 1998;96(3):248-252.
Rebeiz JJ, et al. Corticodentatonigral degeneration with neuronal achromasia: A progressive disorder of late adult life. Trans Am Neurol Assoc. 1968;92:23-26.